

PATENT
Customer No. 76,392
Attorney Docket No. SP-02-US-DIV-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Campbell et al.)	Group Art Unit: 1632
Application No.: 09/658,862)	Examiner: D. Crouch
Filed: September 8, 2000)	Confirmation No.: 2555
For: UNACTIVATED OOCYTES AS)	
CYTOPLAST RECIPIENTS FOR)	
NUCLEAR TRANSFER)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Assignee, Roslin Institute (Edinburgh), represents that it is the assignee of the entire right, title and interest in and to the instant application, Application No. 09/658,862, filed September 8, 2000, as evidenced by assignments recorded at Reel 8582, Frames 0263-0264; Reel 9220, Frames 0250-0256; and Reel 017336, Frame 0136.

Assignee, Roslin Institute (Edinburgh), further represents that it is the assignee of the entire right, title and interest in and to U.S. Patent No. 7,304,204; U.S. Patent No. 7,307,198; U.S. Patent No. 7,321,076; U.S. Patent No. 7,326,824; U.S. Patent No. 7,326,825; U.S. Patent No. 7,332,648; U.S. Patent No. 7,361,804; and U.S. Patent 7,432,415; as indicated by assignments recorded at

Reel 8582, Frames 0263-0264; Reel 9220, Frames 0250-0256; and 017336, Frame 0136.

Assignee, Roslin Institute (Edinburgh), further represents that it is the assignee of the entire right, title and interest in and to U.S. Patent No. 7,232,938 and U.S. Patent No. 7,355,094, as evidenced by assignments recorded at Reel 8622, Frames 0299-0300; Reel 9219, Frames 0945-0951; and Reel 017336, Frame 0136.

To obviate a double patenting rejection, assignees hereby disclaim, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of U.S. Patent No. 7,232,938; U.S. Patent No. 7,304,204; U.S. Patent No. 7,307,198; U.S. Patent No. 7,321,076; U.S. Patent No. 7,326,824; U.S. Patent No. 7,326,825; U.S. Patent No. 7,332,648; U.S. Patent No. 7,355,094; U.S. Patent No. 7,361,804; and U.S. Patent 7,432,415. Assignees hereby agree that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Assignees do not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of U.S. Patent No. 7,232,938; U.S. Patent No. 7,304,204; U.S. Patent No. 7,307,198; U.S. Patent

No. 7,321,076; U.S. Patent No. 7,326,824; U.S. Patent No. 7,326,825; U.S. Patent No. 7,332,648; U.S. Patent No. 7,355,094; U.S. Patent No. 7,361,804; and U.S. Patent 7,432,415, as presently shortened by any terminal disclaimer, in the event that the prior patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned is an attorney of record.

Respectfully submitted,

Law Office of Salvatore Arrigo

Dated: May 25, 2009

By: 

Salvatore J. Arrigo
Registration No. 46,063
Telephone: 202.772.1101
Facsimile: 888.866.4907
E-mail: sal@arrigo.us